How to Evaluate an RCM Platform Against Infusion-Specific Revenue Cycle Benchmarks
Infusion centers need RCM platforms built for drug-cost risk, not adapted from general billing.
Infusion centers running buy-and-bill drug programs need revenue cycle management software built around a specific fact: the practice pays for the drug before the payer ever adjudicates the claim. A billing platform built for a general outpatient practice has no native logic for prior authorization renewal cycles, J-code unit verification, or NDC matching, so evaluating RCM vendors for infusion requires a different set of benchmarks. This article lays out those benchmarks, section by section, so a practice can tell whether a platform was built for infusion or just adapted to look like it was.
Infusion Billing's Financial Risk
A denied claim in most outpatient specialties is an inconvenience. Infusion works differently because the practice has already purchased the drug before the payer ever sees the claim. A denial doesn't just mean lost reimbursement for a visit. It means the practice absorbed the full acquisition cost of a biologic that may have run into the thousands or tens of thousands of dollars, with no way to recover it after the fact.
That dollar concentration changes what a workflow failure actually costs. Benefits verification, prior authorization, drug-unit coding, NDC matching, and site-of-care compliance are infusion-specific workflows with no direct equivalent in general medical billing, and each one can sink a claim. A platform built to handle office visits and routine procedures simply has no logic built in for the places where infusion claims actually break.
Payers have also sharpened their scrutiny of this specific service category. Platforms purpose-built for infusion, like Ruby RCM, treat that cash-flow exposure as a foundational design constraint, building prior auth, denial management, and payment reconciliation around the drug-cost risk that defines this specialty from the start.
Why feature checklists fail for infusion RCM platforms
Most RCM platforms, when you ask, will say yes to the same list of features: prior auth tracking, claim submission, denial management, payment posting. Every vendor in the market can check those boxes. A checklist can't tell you if those functions were built around infusion-specific failure points, or built generic and just stretched to fit.
Take denial management as an example. It has no way of seeing that a specific payer is denying a specific biologic at a disproportionate rate, or that renewal timing is the actual driver behind a cluster of rejections.
Software can move claims through a workflow faster than a person can. It's what the platform's prior auth cycle time looks like for recurring infusion treatments, and what its approval rate is broken down by payer. Those are benchmark questions, not checklist questions, and they're the only ones that predict how a platform will actually perform once it's handling live infusion claims.
The prior authorization lifecycle benchmark: what to measure for recurring infusion treatments
Prior authorization is the earliest point in the revenue cycle where infusion-specific failure gets seeded, so it's the right place to start a benchmark-based evaluation. Infusion PA is structurally harder than general PA because the treatments recur. Authorization typically covers a fixed window, and when the renewal lapses, the claim gets denied retroactively, after the drug has already been administered and the practice has already paid for it. That timing makes the renewal cycle, rather than the initial approval, the part of the lifecycle that shows whether a platform was actually built for infusion.
More infusion treatments will need prior authorization heading into 2026, and when the approval process is slow or produces incorrect approvals, treatment gets postponed and revenue is lost. Payers will have to respond faster and support electronic prior-auth workflows, so if a provider can't submit through those channels, it risks denials just for using the wrong format. Many generic platforms haven't built for that compliance dimension.
Evaluating a platform's PA capability means looking at four things: initial authorization approval rate segmented by payer and drug type, authorization cycle time from submission to approval broken out by payer, the reauthorization miss rate showing what percentage of recurring treatment episodes see renewal lapse before the next infusion date, and whether the platform maintains a payer requirements library that updates as policy changes. Because infusion treatments recur and authorization windows are fixed, the benchmark that matters is renewal cycle time, and whether the platform flags expiring authorizations before claims go out the door, a workflow that only appears when a system is built exclusively around infusion's recurring-treatment model instead of adapted from general-practice billing logic.
First-pass claim acceptance and denial rate benchmarks, broken down the way infusion requires
An aggregate denial rate is close to useless for an infusion practice, because infusion denials cluster around specific, identifiable failure points. The benchmark that actually diagnoses a problem is denial rate segmented by drug type, by payer, and by root cause. Insurers now want fuller documentation, more precise coding, and stronger medical necessity justification before they'll pay an infusion claim, and incomplete documentation is now one of the fastest-growing denial categories in the specialty. Payers now run clinical notes through NLP tools and compare them against submitted codes, so a vague medical necessity statement or a missing comorbidity can trigger an automatic denial. That failure mode demands precision at the individual encounter level, not a general coding review applied after the fact.
A platform needs to be able to track and report denials across several specific categories: prior authorization that's missing, expired, or mismatched to the therapy actually administered; J-code unit errors where billed units don't match the administered dose; an NDC number that's absent or doesn't match the J-code; medical necessity documentation that falls short of supporting the diagnosis-drug combination submitted; site-of-care restrictions applied after the claim goes in, where the payer required a different care setting; and gaps in dosage accuracy or vial wastage documentation. That drop didn't come from a general push to "reduce denials." It came from isolating one identifiable, category-specific error and correcting it, which is exactly the kind of root-cause specificity an aggregate denial number can never reveal.
High-performing infusion organizations treat every denied claim as feedback about operational performance, not just a one-off problem to appeal and move past, and that shift in mindset changes how improvement happens. Denial rate by root cause is the diagnostic tool that explains why. Both need to be tracked at the individual infusion-claim level for the data to be actionable.
J-code and drug-unit billing accuracy as a revenue benchmark, not a coding check
Drug-unit billing accuracy carries the highest financial stakes of any coding function in infusion, because when a J-code unit count is wrong, the margin loss is direct and permanent. The practice already paid acquisition cost for the full dose. If the units billed don't match what was administered, it gets reimbursed for only a fraction of that cost, and that gap doesn't come back through an appeal.
In a buy-and-bill arrangement, the provider purchases the drug, administers it, and bills the payer separately for the drug itself through the J-code and for the administration through a CPT code. Managing which payers require which model across multiple locations is a platform capability, not just a note in an operations manual.
Payers are increasing audit activity with detailed attention to dosage accuracy, correct HCPCS codes for medication and supplies, medical necessity evidence, prior authorization compliance, and proof-of-service and infusion time logs. A platform with no automated drug-unit validation against the encounter record can't stop the most common and most expensive buy-and-bill error, so it reports clean first-pass numbers that mask margin erosion.
Underpayment detection rate as a benchmark for contract-level remittance reconciliation
A paid claim isn't automatically a correctly paid claim. In infusion, the gap between what a payer owes under its contract and what it actually remits is wide enough to count as a structural revenue leak, one that most general-purpose RCM platforms never catch. Underpayment happens when a payer remits less than the contracted rate for a drug, an administration code, or a modifier combination. Infusion remittances are so line-item complex that this gap stays invisible unless someone matches contracts at the drug-unit level.
The loss comes from a quiet mechanism: underpayments that don't surface because no one matches remittances against contracted rates at the drug-unit level. A platform evaluation needs to answer three specific questions here. And does it track underpayment rate as a reported KPI with a defined threshold that triggers review? High-performing infusion RCM operations hold underpayment rate under a threshold that triggers active intervention, and platforms that don't track this metric at all are producing payment reports that look clean while hiding real losses. That same blind spot carries forward into AR: an undetected underpayment can make a claim look resolved on paper while actual revenue has already been written off and lost.
AR aging benchmarks and infusion-specific dollar concentration
In infusion, AR aging is a concentration problem. An infusion practice needs value-weighted aging that surfaces which specific claims, by drug, payer, and dollar amount, are approaching the point where a payer starts treating them as non-collectible.
In AR management, staff without automated dollar-value prioritization end up working the highest-volume bucket instead of the highest-dollar-risk one, losing real revenue in the process. The strongest infusion organizations build revenue cycle processes that prevent unnecessary denials, cut down on rework, and give you a predictable path to payment from the first scheduling touchpoint on. AR aging is the final scorecard on whether those upstream processes worked. High AR days in an infusion practice are almost always a downstream symptom of a PA failure, a denial pattern, or an underpayment that should have been caught earlier in the cycle.
Denial root-cause visibility as a platform architecture test, not a reporting feature
Whether a platform can show denial root causes by payer and drug type reveals more about how it was built than any other single benchmark, because infusion denial patterns are payer-specific and drug-specific in ways that generic denial categories can't capture. If a platform can't segment along those two dimensions, it can't separate a meaningful pattern from background noise.
Payer policy updates don't cause revenue leakage on their own. Failure to operationalize those updates does, and a platform that can't show which payer changed which policy and how that change is showing up in denial patterns can't support the kind of response that prevents repeat losses. A useful test for any vendor: ask them to produce a denial report showing denial rate by payer and by J-code, with root-cause categories that separate authorization failures from documentation failures from coding errors. A platform built for general billing will hand back a report segmented by CARC code, which tells a practice what the payer said but not what actually went wrong operationally. A platform built for infusion will map that CARC code to the actual operational failure point, whether that's a missed PA renewal, a unit-count error, or a missing NDC, and show how often each one occurs broken down by payer and by drug.
The distinction between tracking denials and understanding them is the distinction between software and operational design. Denial pattern visibility also gives practice leadership something harder to get otherwise: documented, payer-specific data for negotiating, escalating, or restructuring a contract where one payer is denying at a disproportionate rate.
How to run a benchmark-based platform evaluation in practice
In a benchmark-based evaluation, you ask vendors for actual performance data against infusion-specific KPIs drawn from their existing infusion clients. It is documented outcome metrics gathered across three stages, not a product demo or a reference call.
Stage one defines a current baseline before looking at any vendor. Measure the practice's own performance on the benchmarks covered above: PA approval rate by payer, first-pass denial rate by drug type, underpayment detection rate, and AR days for drug claims versus administration claims. Without that baseline, there's no way to judge whether a new platform represents an actual improvement or just a different set of problems.
In stage two, you request infusion-specific performance evidence from each vendor under consideration. Ask for documented performance from current infusion clients of comparable size and payer mix, not projected outcomes and not case studies borrowed from unlike settings. Ask if the platform tracks and reports denial rate by J-code and payer combination, reauthorization miss rate by therapy type, and underpayment rate as a defined, monitored KPI.
In stage three, you evaluate the operational model that sits alongside the platform. Technology provides visibility, but people drive the improvement, and an evaluation that skips the operational team behind the software is only assessing half the system. Ask how that team handles judgment calls a rules engine can't make on its own: a payer policy change in the middle of an authorization cycle, a novel biologic that hasn't been assigned a J-code yet, a site-of-care dispute on a high-dollar claim. Watch for warning signs along the way, including denial reporting available only at the aggregate or CARC-code level with no drug-type or payer breakdown, prior auth management that doesn't track renewal timelines separately from initial approval, no line-level drug-unit verification before submission, payment posting that never compares remittances against contracted rates at the J-code level, and AR aging reports built around volume instead of dollar value.
A platform that can answer these benchmark questions with real numbers from real infusion clients has demonstrated something a feature list never can: that it was built to carry the specific financial risk infusion billing creates, not adapted after the fact to tolerate it.
